SEC Form 4 · accession 0000899243-18-027480

LogicBio Therapeutics, Inc. · LOGC

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Tomer Kariv

Director

Period of report

Oct 23, 2018

Accepted (ET)

Oct 25, 2018 · 6:27 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001664106

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Oct 23, 2018	C	674,431	—	A	674,431	I	See Footnote
Common Stock^F1,F3	Oct 23, 2018	C	364,643	—	A	1,039,074	I	See Footnote
Common Stock^F1,F4	Oct 23, 2018	C	328,339	—	A	1,367,413	I	See Footnote
Common Stock^F2	Oct 23, 2018	P	207,151	$10.00	A	1,574,564	I	See Footnote
Common Stock^F3	Oct 23, 2018	P	112,000	$10.00	A	1,686,564	I	See Footnote
Common Stock^F4	Oct 23, 2018	P	100,849	$10.00	A	1,787,413	I	See Footnote

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series B Convertible Preferred Stock^F2,F1	—	Oct 23, 2018	C	1,288,116	D	—	—	Common Stock	674,431	692,982	I
Series B Convertible Preferred Stock^F3,F1	—	Oct 23, 2018	C	696,444	D	—	—	Common Stock	364,643	328,339	I
Series B Convertible Preferred Stock^F4,F1	—	Oct 23, 2018	C	627,105	D	—	—	Common Stock	328,339	0	I

Explanation of responses

F1Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock.
F2Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax IV GP L.P. ("Pontifax IV") is the general partner of Israel IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the general partner of Pontifax IV. The Reporting Person is a Managing Partner of Management 4. By virtue of this relationship, the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise of such portion of these securities in which he has no pecuniary interest.
F3Represents shares of the Issuer held by Pontifax (China) IV, L.P. ("China IV"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by China IV. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Exchange Act or otherwise of such portion of these securities in which he has no pecuniary interest.
F4Represents shares of the Issuer held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Pontifax IV is the general partner of Cayman IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Exchange Act or otherwise of such portion of these securities in which he has no pecuniary interest.